SAM CHUN DANG PHARM. CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128,800 KRW | +4.29% |
|
+1.82% | +66.62% |
| Sales 2022 | 177B 130M | Sales 2023 | 193B 141M | Capitalization | 1,759B 1.29B |
|---|---|---|---|---|---|
| Net income 2022 | 5.84B 4.27M | Net income 2023 | -10.38B -7.6M | EV / Sales 2022 | 5.4 x |
| Net cash position 2022 | 9.66B 7.07M | Net cash position 2023 | 39.12B 28.64M | EV / Sales 2023 | 8.93 x |
| P/E ratio 2022 |
166
x | P/E ratio 2023 |
-167
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.41% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.29% | ||
| 1 week | +1.82% | ||
| Current month | +7.96% | ||
| 1 month | +12.88% | ||
| 3 months | +59.60% | ||
| 6 months | +92.53% | ||
| Current year | +66.62% |
1 week
118 600.00
130 900.00
1 month
99 200.00130 900.00
Current year
61 900.00151 200.00
1 year
49 750.00151 200.00
3 years
26 100.00151 200.00
5 years
21 350.00151 200.00
10 years
7 020.00151 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
In-Seok Jeon
CEO | Chief Executive Officer | 50 | - |
Dae-In Yoon
CHM | Chairman | 74 | - |
Sae-Young Chun
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dae-In Yoon
CHM | Chairman | 74 | - |
In-Seok Jeon
CEO | Chief Executive Officer | 50 | - |
Yong-Gwan Kim
BRD | Director/Board Member | 59 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.59% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 114 M€ | +5.97% | - | |
| 0.00% | 32 M€ | +5.12% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 128,800 | +4.29% | 751 481 |
| 24-06-11 | 123,500 | +1.65% | 1,062,574 |
| 24-06-10 | 121,500 | -4.33% | 572,242 |
| 24-06-07 | 127,000 | +2.01% | 647,701 |
| 24-06-05 | 124,500 | -1.58% | 386,230 |
End-of-day quote Korea S.E., June 11, 2024
More quotes
SAM CHUN DANG PHARM. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Companyâs products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
Sector
Pharmaceuticals
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +66.62% | 2.04B | |
| +19.64% | 43.03B | |
| +23.86% | 22.7B | |
| +17.44% | 15.07B | |
| +23.64% | 14.77B | |
| +59.16% | 13.05B | |
| -0.05% | 6.79B | |
| -14.19% | 6.58B | |
| -8.87% | 5.73B | |
| +13.42% | 5.5B |
- Stock Market
- Equities
- A000250 Stock
